MedTrace Logo

Immunological Phenotype of Desmoid-fibromatosis-affected Patients.

NCT07496242 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-03-27

No results posted yet for this study

Summary

This observational study aims to characterize the molecular, phenotypic, and functional inflammatory and immunological profile of patients with sporadic desmoid-type fibromatosis undergoing either active surveillance or systemic therapy. The study includes analysis of the tumor immune microenvironment (TIME), circulating immune and inflammatory molecules, immune cell subsets, and circulating tumor DNA (ctDNA). The goal is to identify biomarkers associated with spontaneous or treatment-induced tumor regression and to evaluate potential correlations with specific ß-catenin mutations.

Conditions

  • Desmoid-Type Fibromatosis

Sponsors & Collaborators

  • Campus Biomedico - Roma

    collaborator UNKNOWN

  • Candiolo Cancer Institute - IRCCS

    collaborator OTHER

  • Azienda Ospedaliero-Universitaria Careggi

    collaborator OTHER

  • Azienda USL Toscana Centro

    collaborator OTHER

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

    collaborator OTHER

  • Erasmus University Rotterdam

    collaborator OTHER

  • Istituto Oncologico Veneto IRCCS

    collaborator OTHER

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    lead OTHER

Principal Investigators

  • Chiara Colombo, MD, Surgical Oncologist · Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-27
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • Italy
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07496242 on ClinicalTrials.gov